LIPO-202: Phase II started

Lithera began the double-blind, placebo-controlled, U.S. Phase IIb RESET trial to evaluate 3 doses of subcutaneous LIPO-202 injected in the abdomen weekly for 8 weeks in about 500 healthy patients wit...